Bortezomib-D8 (Major) (CAS 179324-69-7 unlabeled)
See product citations (1)
QUICK LINKS
Bortezomib-D8 (Major), often utilized as an analytical reference standard, plays a role in various research applications, particularly in the study of proteasome inhibition mechanisms. This deuterated version of bortezomib offers researchers a stable isotope-labeled compound that is instrumental in mass spectrometry, enabling precise tracking of the compound′s behavior and metabolism in biological systems. Its utility in research extends to the investigation of the ubiquitin-proteasome pathway, a cellular process integral to protein degradation and turnover, which is fundamental in understanding cellular regulation and protein homeostasis. Scientists also leverage Bortezomib-D8 (Major) in the field of proteomics to dissect protein expression patterns and to explore the intricate dynamics within signal transduction pathways.
Bortezomib-D8 (Major) (CAS 179324-69-7 unlabeled) References
- Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice. | Zhang, L. and Mager, DE. 2015. J Pharmacokinet Pharmacodyn. 42: 541-52. PMID: 26391023
- Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. | Rahman, MA., et al. 2019. Br J Cancer. 121: 545-555. PMID: 31413318
- Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis. | Fujimoto, Y., et al. 2021. Cancers (Basel). 13: PMID: 34830830
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bortezomib-D8 (Major), 1 mg | sc-217786 | 1 mg | $549.00 |